Literature DB >> 17294310

Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients.

D Le1, D Marks, E Lyle, C L Corless, B S Diggs, B A Jobe, T Kay, C W Deveney, B M Wolfe, C T Roberts, R W O'Rourke.   

Abstract

BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a major cause of liver disease in morbidly obese patients. Clinical predictors of NASH remain elusive, as do molecular mechanisms of pathogenesis.
METHODS: A series of 35 morbidly obese patients undergoing bariatric surgery had a liver biopsy performed for standard histologic analysis. In addition, RNA was obtained from liver tissue and analyzed for leptin receptor gene expression. Regression analysis was used to correlate clinical variables, including serum leptin levels and hepatic leptin receptor gene expression, with the presence of histologically confirmed NASH.
RESULTS: Of the 35 subjects enrolled, 29% had steatosis only, 60% had NASH, and 11% had normal liver histology. Among the clinical variables studied, only diabetes mellitus was an independent predictor of NASH. There was a trend toward lower levels of mRNA encoding the long form of the leptin receptor in hepatic tissue from patients with NASH compared to those with steatosis only.
CONCLUSIONS: Diabetes mellitus is associated with an increased risk of NASH in obese patients. Downregulation of hepatic leptin receptor may play a role in the pathogenesis of NASH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294310     DOI: 10.1007/s00464-006-9185-5

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  52 in total

1.  Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation.

Authors:  R L Martin; E Perez; Y J He; R Dawson; W J Millard
Journal:  Metabolism       Date:  2000-11       Impact factor: 8.694

2.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

3.  Prevalence of fatty liver in a general population of Okinawa, Japan.

Authors:  H Nomura; S Kashiwagi; J Hayashi; W Kajiyama; S Tani; M Goto
Journal:  Jpn J Med       Date:  1988-05

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

6.  Nonalcoholic steatohepatitis and the "bright liver syndrome": should a recently expanded clinical entity be further expanded?

Authors:  A Lonardo; M Bellini; E Tondelli; M Frazzoni; A Grisendi; M Pulvirenti; G Della Casa
Journal:  Am J Gastroenterol       Date:  1995-11       Impact factor: 10.864

7.  Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Jeanne M Clark; Amir R A Alkhuraishi; Steven F Solga; Patricia Alli; Anna Mae Diehl; Thomas H Magnuson
Journal:  Obes Res       Date:  2005-07

8.  Hypothalamic leptin receptor and signaling molecule expressions in cafeteria diet-fed rats.

Authors:  Charles Plut; Catherine Ribière; Yves Giudicelli; Jean-Pierre Dausse
Journal:  J Pharmacol Exp Ther       Date:  2003-09-09       Impact factor: 4.030

9.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

10.  Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction.

Authors:  J A Cioffi; A W Shafer; T J Zupancic; J Smith-Gbur; A Mikhail; D Platika; H R Snodgrass
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  8 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells.

Authors:  Xiao-Min Xin; Mu-Xiao Zhong; Gong-Li Yang; Yao Peng; Ya-Li Zhang; Wei Zhu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Low density lipoprotein (LDL) receptor-related protein 6 (LRP6) regulates body fat and glucose homeostasis by modulating nutrient sensing pathways and mitochondrial energy expenditure.

Authors:  Wenzhong Liu; Rajvir Singh; Cheol Soo Choi; Hui-Young Lee; Ali R Keramati; Varman T Samuel; Richard P Lifton; Gerald I Shulman; Arya Mani
Journal:  J Biol Chem       Date:  2012-01-09       Impact factor: 5.157

4.  Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

Authors:  Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2009-07-15       Impact factor: 4.129

Review 5.  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Stergios A Polyzos; Konstantinos N Aronis; Jannis Kountouras; Dimitrios D Raptis; Maria F Vasiloglou; Christos S Mantzoros
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

6.  Adiponectin but not leptin is involved in early hepatic disease in morbidly obese patients.

Authors:  Anna Katharine Hindle; Claire Edwards; Alisha Mendonsa; Marcos Rojkind; Tim McCaffrey; Sidney Fu; Fred Brody
Journal:  Surg Endosc       Date:  2009-12-30       Impact factor: 4.584

7.  Thyroid hormone-related regulation of gene expression in human fatty liver.

Authors:  Jussi Pihlajamäki; Tanner Boes; Eun-Young Kim; Farrell Dearie; Brian W Kim; Joshua Schroeder; Edward Mun; Imad Nasser; Peter J Park; Antonio C Bianco; Allison B Goldfine; Mary Elizabeth Patti
Journal:  J Clin Endocrinol Metab       Date:  2009-06-23       Impact factor: 5.958

8.  IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study.

Authors:  Xu Chen; Yi Tang; Shen Chen; Wenhua Ling; Qing Wang
Journal:  Endocr Connect       Date:  2021-10-13       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.